Careers Header Bg
Regask Pharma Japan 2025 Landing Page
REGASK JOINS

Pharma Japan 2025

SEPTEMBER 9-10, 2025  |  JAPAN

The Westin, Tokyo

Meet us at Pharma Japan 2025 Meet us at DIA Singapore 2025

Meet our team at Pharma Japan 2025

Join Oliver Stein, Business Development Director & Natsumi Yamada, Customer Success Manager at RegASK, as they represents us at Pharma Japan 2025. This is a great opportunity to connect, explore AI-driven regulatory intelligence, and see how RegASK empowers smarter, faster compliance in dynamic life sciences markets.

Pharma Japan 2025 Attendees 4

Oliver Stein

Business Development Director

Natsumi Yamada

Customer Success Manager



Bg Flip Card 1

Pharma Japan 2025

Reuters Events: Pharma Japan 2025 is Japan’s largest and only pharma executive conference, bringing together top leaders from commercial, sales, marketing, medical, patient engagement, RWE, clinical, market access, digital, IT, and more to shape the future of Japanese pharmaceutical innovation

Key themes include:

  • The urgent shift toward a customer-centric business model
  • Integration of commercial, marketing, R&D, clinical, data, and digital functions with patient experience at the center
  • AI innovation to personalize engagement and optimize resources, highlighting interactive, actionable programming such as debates, hackathons, and real-world pilot discussions

Venue & Schedule:

📍 The Westin Tokyo, 1 Chome-4-1 Mita, Meguro City, Tokyo 153-8580, Japan
🗓 September 9–10, 2025 | 9:00 AM – 5:00 PM (GMT+9)

What RegASK Brings to Pharma

At RegASK, we support pharmaceutical companies with AI-driven regulatory intelligence to help them stay ahead in a rapidly evolving landscape.

Here’s how we add value to the industry:

  • Navigate Japan’s complex regulations with monitoring and expert insights

  • Accelerate compliance workflows through AI-enabled automation and predictive intelligence

  • Ensure global-to-local alignment for pharma regulatory strategies across APAC and worldwide

  • Reduce risk and optimize resources with proactive alerts and actionable recommendations

  • Empower innovation by freeing teams to focus on patient-centric initiatives while RegASK manages compliance complexities

By combining regulatory expertise with advanced AI, RegASK enables pharma companies to deliver innovation with confidence, speed, and compliance.

Meet us at Pharma Japan 2025! Meet us at DIA Singapore 2025!

Our solution

RegASK leverages advanced AI and machine learning to help businesses in highly regulated industries streamline their regulatory compliance processes and stay ahead of the curve. Our cutting-edge solution automates regulatory research, provides vital insights, and empowers regulatory affairs teams to become strategic partners in driving business growth.

Resources

Navigating a Potential U.S. Government Shutdown: Implic…
As legislators in Washington, DC, face a critical March 14th deadline to finalize federal spending, the possibility of a U.S. government shu…
Read more
RegASK Featured in Gartner’s Market Guide for Regulat…
We’re thrilled to share that RegASK has been included in Gartner’s Market Guide for Regulatory Intelligence Solutions! This recognition …
Read more
The 2025 State of Regulatory Affairs and Compliance Rep…
Is your organization prepared for 2025’s regulatory complexities? The regulatory landscape in 2025 is more complex than ever, with new adv…
Read more
ANSM (France) Clarifies CE Mark Exemption Process for M…
On January 27, 2025, the National Security Agency of Medicines and Health Products (ANSM) in France issued a key update regarding the proces…
Read more
US FDA Announces Draft Guidance on AI Use in Regulatory…
On January 6, 2025, the U.S. Food and Drug Administration (FDA) announced the release of a draft guidance titled “Considerations for the U…
Read more
US FDA Announces Public Meeting on Paediatric Legislati…
The Food and Drug Administration (FDA) has scheduled a public meeting titled “Interested Parties Meeting: Implementation of the Best Pharm…
Read more
FDA (USA) Establishes New Center for Real-World Evidenc…
On December 12, 2024, the U.S. Food and Drug Administration (FDA) announced the creation of the Center for Real-World Evidence and Innovatio…
Read more
Portuguese Industry Opposes U.S. Proposal for Cancer Wa…
The United States Health Authority is considering the introduction of mandatory cancer warning labels on alcoholic beverages, a measure simi…
Read more